Transcatheter arterial chemoembolization for hepatocellular carcinoma

Area of Science:

• Hepatobiliary Medicine
• Interventional Radiology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) remains a significant global health challenge.
• Transcatheter arterial chemoembolization (TACE) is a primary treatment modality for unresectable HCC.
• Previous studies have reported varying survival rates following TACE.

Purpose of the Study:

• To analyze factors influencing survival duration in HCC patients treated with TACE.
• To evaluate the impact of patient selection and technical advancements on TACE outcomes.
• To establish prognostic indicators for HCC patients undergoing TACE.

Main Methods:

• Retrospective analysis of 329 HCC cases treated with TACE (1983-1990).
• Kaplan-Meier method for survival analysis.
• Evaluation of clinical factors (Child's status), tumor characteristics (size, capsule integrity), and vascular status (portal vein patency).

Main Results:

• Overall 1-, 2-, and 3-year survival rates were 50%, 25%, and 15%, respectively (median survival: 12.7 months).
• Improved survival observed compared to earlier cohorts, attributed to patient selection and superselective technique.
• Favorable prognostic factors included single lesions <5 cm, intact capsule, patent portal vein, and good Child's status.

Conclusions:

• Careful patient selection based on Child's status and refined superselective TACE techniques can improve survival in HCC.
• Tumor characteristics and portal vein status are critical determinants of treatment success.
• Periodic imaging (ultrasonography, CT, angiography) is essential for monitoring and determining the need for repeat TACE.